Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.

Hirotaka WatadaMasanari ShiramotoShinya UedaWeifeng TangMichiko AsanoFredrik ThorénHyosung KimToshitaka YajimaDavid W BoultonEiichi Araki

Published in: Diabetes, obesity & metabolism (2018)

The PK and safety profiles of dapagliflozin in Japanese patients with T1D were consistent with previous studies, but with an unanticipated attenuation of the PD dose-response measured as UGE.

Keyphrases

type diabetes
glycemic control
case control
metabolic syndrome
adipose tissue
skeletal muscle
weight loss